Plain-English answers
Strength and recovery peptides, explained without the marketing.
Your one-stop resource for strength, recovery, and performance peptides — research, dosing tools, side-effect guides, and plain-English answers.
Educational content. Not medical advice.
Start here
Pick your peptide
Each tile opens to a deep dive — mechanism, dosing, side effects, stacks, and every question we've answered about it.
- 53 posts
BPC-157
Healing & soft tissue
Explore - 23 posts
TB-500
Tendon & ligament repair
Explore - 39 posts
Ipamorelin + CJC-1295
GH pulse stack
Explore - 15 posts
IGF-1 LR3
Direct anabolic
Explore - 11 posts
Tesamorelin
Visceral fat loss
Explore - 15 posts
MOTS-c
Mitochondrial & metabolic
Explore - 12 posts
GHK-Cu
Skin, hair, anti-aging
Explore - 21 posts
Side effects & sourcing
What can go wrong
Explore
Take the 3-question peptide quiz.
Goal × experience × route → the peptide with the strongest evidence for your situation. We'll be honest when injection-only options dominate the choice.
Takes about a minute.
Most asked
Quick answers
Can I take epitalon every day?
You can within a course, but epitalon is usually run in short cycles — a 10–20 day course a few times a year — not continuously, mirroring how its research was done.
Can peptides raise blood pressure?
Some can, indirectly — GH peptides via water retention, MK-677 notably. Others like BPC-157 may be neutral or supportive. It depends heavily on the specific peptide.
Does IGF-1 LR3 cause water retention?
Some, but less than GH peptides. IGF-1 LR3's bigger concerns are hypoglycemia and gut/organ growth — water retention is usually mild and not its main side effect.
Does tesamorelin build muscle?
Not really — tesamorelin is a visceral-fat peptide. It raises GH and IGF-1, which gives mild lean-tissue support, but it's not a muscle-builder like IGF-1 LR3.
What we're watching
This week's reading
The fast-moving stuff — recent FDA shifts, study readouts, and clinician pushback worth your time. Updated as the news moves.
- NewsJune 3, 2026
CagriSema's mixed data lands at ADA 2026
Novo's amylin/GLP-1 combo CagriSema posts strong REDEFINE 1 numbers but missed its head-to-head goal vs tirzepatide. New analyses arrive at ADA's June 5–8 meeting.
- NewsJune 3, 2026
Survodutide's obesity data heads to ADA 2026
Boehringer's glucagon/GLP-1 dual agonist survodutide hit 16.6% weight loss at 76 weeks in Phase 3 SYNCHRONIZE-1. Full data lands at ADA's June 5–8 meeting.
- ArticleJune 3, 2026
5-Amino-1MQ vs Berberine for Metabolism
5-Amino-1MQ inhibits the NNMT enzyme; berberine activates AMPK. Both target metabolism differently. Here's how they compare on evidence, effect, and cost.
From the blog
Go deeper
5-Amino-1MQ vs Berberine for Metabolism
5-Amino-1MQ inhibits the NNMT enzyme; berberine activates AMPK. Both target metabolism differently. Here's how they compare on evidence, effect, and cost.
Epitalon and Melatonin: Sleep and Aging
Epitalon is studied for restoring melatonin rhythm and pineal function with age. Here's the sleep-and-longevity evidence, what's real, and what's overstated.
IGF-1 LR3 Site-Specific Growth: Myth or Real?
Can you grow a specific muscle by injecting IGF-1 LR3 into it? The site-specific growth idea is mostly a myth for LR3 — here's why, and what's actually happening.
Peptide news
What's happening now
CagriSema's mixed data lands at ADA 2026
Novo's amylin/GLP-1 combo CagriSema posts strong REDEFINE 1 numbers but missed its head-to-head goal vs tirzepatide. New analyses arrive at ADA's June 5–8 meeting.
Survodutide's obesity data heads to ADA 2026
Boehringer's glucagon/GLP-1 dual agonist survodutide hit 16.6% weight loss at 76 weeks in Phase 3 SYNCHRONIZE-1. Full data lands at ADA's June 5–8 meeting.